Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275402 · ClinicalTrials.gov registry record · Phase 2
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
A Phase 2 study, sponsored by Y-mAbs Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT03275402 is a Phase 2 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 52 participants.
The verdict
NCT03275402, a Phase 2 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety
Interventions
- BIOLOGICAL 131I-omburtamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-12-11 |
| Est. Completion | 2023-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275402
The ClinicalTrials.gov registry entry for NCT03275402 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Y-mAbs Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 131I-omburtamab is the first listed.
NCT03275402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275402 about?
NCT03275402 is a clinical study titled "131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases". Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety
What is the current status of trial NCT03275402?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2018-12-11. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT03275402?
The interventions under investigation include: 131I-omburtamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03275402?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.